1.  Home
  2. Whitepapers
  3. A New HTS Platform (96-well plate) for Early Muscle Drug Discovery

A New HTS Platform (96-well plate) for Early Muscle Drug Discovery

Download Whitepaper

A New HTS Platform (96-well plate) for Early Muscle Drug Discovery

Download Whitepaper
The FDSS/µCELL from Hamamatsu was used to measure intracellular calcium transients in real-time, the response to electrical stimulation of MyoScreen™, a patient-derived skeletal muscle in vitro high-throughput platform, as well as the functionality of the excitation-contraction coupling (ECC) machinery were evaluated. A novel stimulator of myofiber regeneration/repair, recently identified by CYTOO in an “in-house” drug screen, was further characterized on the FDSS-MyoScreen™ system. We found that the hit compound significantly increased levels of myoplasmic calcium compared to non-treated controls upon electrical stimulation. Overall, the Hamamatsu FDSS/µCELL electrical stimulation and calcium imaging platform combined with the MyoScreen™ in vitro myotube model provides a relevant screening system for modulators of calcium levels in the context of skeletal muscle exercise and performance.

Download Whitepaper Now